{
    "root": "4dfbf0f3-52f5-4461-b645-b8eb8846a8e1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Inrebic",
    "value": "20250512",
    "ingredients": [
        {
            "name": "FEDRATINIB HYDROCHLORIDE",
            "code": "UH9J2HBQWJ"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "inrebic® indicated treatment adult patients intermediate-2 high-risk primary secondary ( post-polycythemia vera post-essential thrombocythemia ) myelofibrosis ( mf ) .",
    "contraindications": "• recommended : 400 mg orally daily without food patients baseline platelet count greater equal 50 × 10 9 /l ( 2.2 ) . • patients difficulty swallowing capsules whole nasogastric tube , content capsule ( ) may dispersed ensure ® plus ( 2.2 ) . • reduce dose patients taking strong cyp3a inhibitors severe renal impairment ( 2.3 , 2.4 , 7.1 , 8.6 ) .",
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "INREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).",
    "contraindications_original": "• Recommended Dosage: 400 mg orally once daily with or without food for patients with a baseline platelet count of greater than or equal to 50 × 10 9 /L ( 2.2 ). • For patients who have difficulty swallowing capsules whole or those with a nasogastric tube, the content of the capsule(s) may be dispersed in Ensure ® Plus ( 2.2 ). • Reduce dose for patients taking strong CYP3A inhibitors or with severe renal impairment ( 2.3 , 2.4 , 7.1 , 8.6 ).",
    "adverseReactions_original": "None."
}